159 related articles for article (PubMed ID: 7813708)
1. Life expectancy in primary myelodysplastic syndromes: a prognostic score based upon histopathology from bone marrow biopsies of 569 patients.
Maschek H; Gutzmer R; Choritz H; Georgii A
Eur J Haematol; 1994 Nov; 53(5):280-7. PubMed ID: 7813708
[TBL] [Abstract][Full Text] [Related]
2. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
[TBL] [Abstract][Full Text] [Related]
3. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
[TBL] [Abstract][Full Text] [Related]
4. Comparison of scoring systems in primary myelodysplastic syndromes.
Maschek H; Gutzmer R; Choritz H; Georgii A
Ann Hematol; 1995 Jun; 70(6):301-8. PubMed ID: 7632809
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in myelodysplastic syndromes: analysis of five scoring systems.
Rubio-Felix D; Giraldo P; Franco E; Gimeno J; Giralt M
Hematol Oncol; 1995; 13(3):139-52. PubMed ID: 7622144
[TBL] [Abstract][Full Text] [Related]
6. Proliferative indices, cytogenetics, immunophenotye and other prognostic parameters in myelodysplastic syndromes.
Varma N; Varma S
Indian J Pathol Microbiol; 2008; 51(1):97-101. PubMed ID: 18417875
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes.
Jacobs RH; Cornbleet MA; Vardiman JW; Larson RA; Le Beau MM; Rowley JD
Blood; 1986 Jun; 67(6):1765-72. PubMed ID: 3708160
[TBL] [Abstract][Full Text] [Related]
8. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
Aul C; Gattermann N; Heyll A; Germing U; Derigs G; Schneider W
Leukemia; 1992 Jan; 6(1):52-9. PubMed ID: 1736014
[TBL] [Abstract][Full Text] [Related]
9. [Myelosclerosis in myelodysplastic syndromes (MDS). Retrospective analysis of 232 patients with MDS].
Maschek H; Kaloutsi V; Werner M; Bandecar K; Buhr T; Georgii A
Verh Dtsch Ges Pathol; 1990; 74():144-8. PubMed ID: 1708573
[TBL] [Abstract][Full Text] [Related]
10. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis.
Ohshima K; Karube K; Shimazaki K; Kamma H; Suzumiya J; Hamasaki M; Kikuchi M
Leuk Lymphoma; 2003 Aug; 44(8):1339-46. PubMed ID: 12952227
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of 4 prognostic scoring systems in 197 myelodysplastic syndrome patients].
Rubio-Félix D; Giraldo MP; Perella M; Gimeno J; Franco E; Giralt M
Sangre (Barc); 1991 Dec; 36(6):463-9. PubMed ID: 1812580
[TBL] [Abstract][Full Text] [Related]
12. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.
Wimazal F; Krauth MT; Vales A; Böhm A; Agis H; Sonneck K; Aichberger KJ; Mayerhofer M; Simonitsch-Klupp I; Müllauer L; Sperr WR; Valent P
Leuk Lymphoma; 2006 Mar; 47(3):451-60. PubMed ID: 16396768
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes.
Shimazaki K; Ohshima K; Suzumiya J; Kawasaki C; Kikuchi M
Br J Haematol; 2000 Sep; 110(3):584-90. PubMed ID: 10997968
[TBL] [Abstract][Full Text] [Related]
15. Hematologic, clinical, and cytogenetic analysis in 109 patients with primary myelodysplastic syndrome. Prognostic significance of morphology and chromosome findings.
Parlier V; van Melle G; Beris P; Schmidt PM; Tobler A; Haller E; Bellomo MJ
Cancer Genet Cytogenet; 1994 Dec; 78(2):219-31. PubMed ID: 7828157
[TBL] [Abstract][Full Text] [Related]
16. Refractory cytopenias: clinical course according to bone marrow cytology and cellularity.
Riccardi A; Giordano M; Girino M; Cazzola M; Montecucco CM; Cassano E; Danova M; Ucci G; Castello A; Coci A
Blut; 1987 Mar; 54(3):153-63. PubMed ID: 3814832
[TBL] [Abstract][Full Text] [Related]
17. Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis.
Maschek H; Kaloutsi V; Rodriguez-Kaiser M; Werner M; Choritz H; Mainzer K; Dietzfelbinger M; Georgii A
Ann Hematol; 1993 Mar; 66(3):117-22. PubMed ID: 8471656
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic values of in vitro culture growth patterns of marrow granulocyte-macrophage progenitors in patients with myelodysplastic syndrome.
Shih LY; Chiu WF; Lee CT
Leukemia; 1991 Dec; 5(12):1092-8. PubMed ID: 1774958
[TBL] [Abstract][Full Text] [Related]
19. Clinical aspects of the myelodysplastic syndromes (MDS) with special reference to refractory anemia with excess of blasts (RAEB).
Omine M; Yamauchi H
Nihon Ketsueki Gakkai Zasshi; 1989 Jul; 52(4):800-10. PubMed ID: 2618556
[TBL] [Abstract][Full Text] [Related]
20. [Study on prognostic factors in twenty-five patients with myelodysplastic syndrome].
Toyama T; Uno H; Yamashita K; Kubuki Y; Suzuki M; Maeda K; Matsuoka H; Tsubouchi H
Gan To Kagaku Ryoho; 1995 Feb; 22(2):227-32. PubMed ID: 7857097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
